Jacobs Levy Equity Management Inc. Takes Position in PepGen Inc. (NASDAQ:PEPG)

Jacobs Levy Equity Management Inc. purchased a new stake in shares of PepGen Inc. (NASDAQ:PEPG) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 136,262 shares of the company’s stock, valued at approximately $516,000. Jacobs Levy Equity Management Inc. owned 0.42% of PepGen at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Deutsche Bank AG increased its stake in shares of PepGen by 442.5% during the fourth quarter. Deutsche Bank AG now owns 44,735 shares of the company’s stock valued at $170,000 after buying an additional 36,489 shares during the period. Corton Capital Inc. bought a new stake in PepGen during the fourth quarter valued at about $68,000. Bridgeway Capital Management LLC boosted its position in PepGen by 103.1% during the fourth quarter. Bridgeway Capital Management LLC now owns 98,900 shares of the company’s stock valued at $375,000 after purchasing an additional 50,200 shares in the last quarter. Bank of America Corp DE boosted its position in PepGen by 54.7% during the fourth quarter. Bank of America Corp DE now owns 53,868 shares of the company’s stock valued at $204,000 after purchasing an additional 19,056 shares in the last quarter. Finally, Northern Trust Corp boosted its position in PepGen by 5.4% during the fourth quarter. Northern Trust Corp now owns 157,038 shares of the company’s stock valued at $595,000 after purchasing an additional 7,984 shares in the last quarter. Hedge funds and other institutional investors own 58.01% of the company’s stock.

PepGen Price Performance

Shares of PEPG stock opened at $1.54 on Friday. PepGen Inc. has a 1-year low of $0.88 and a 1-year high of $19.30. The stock’s 50-day moving average is $1.52 and its 200 day moving average is $2.78. The company has a market cap of $50.39 million, a P/E ratio of -0.52 and a beta of 1.39.

PepGen (NASDAQ:PEPG) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20). On average, analysts anticipate that PepGen Inc. will post -2.73 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright dropped their price objective on PepGen from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday, May 9th.

Insiders Place Their Bets

In other PepGen news, CEO James G. Mcarthur purchased 41,500 shares of the stock in a transaction on Tuesday, April 8th. The stock was acquired at an average price of $1.15 per share, with a total value of $47,725.00. Following the completion of the acquisition, the chief executive officer now owns 103,913 shares in the company, valued at $119,499.95. The trade was a 66.49% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 5.20% of the company’s stock.

PepGen Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.